<div id="readability-page-1"><p>Merit Financial Group LLC lifted its holdings in shares of  Abbott Laboratories (NYSE:ABT - Free Report) by 32.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 81,264 shares of the healthcare product maker's stock after purchasing an additional 20,035 shares during the quarter. Merit Financial Group LLC's holdings in Abbott Laboratories were worth $10,884,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Abbott Laboratories</strong> alerts:</span></p></div><ul><li>Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength</li></ul><p>Several other institutional investors have also made changes to their positions in the stock. IMG Wealth Management Inc. increased its stake in  Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock worth $26,000 after acquiring an additional 167 shares during the period.  Anfield Capital Management LLC grew its holdings in shares of  Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock worth $32,000 after purchasing an additional 104 shares in the last quarter.  Delos Wealth Advisors LLC bought a new position in shares of  Abbott Laboratories in the second quarter worth $32,000.  Curio Wealth LLC raised its stake in  Abbott Laboratories by 15,250.0% in the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock valued at $42,000 after purchasing an additional 305 shares in the last quarter.  Finally, Pineridge Advisors LLC lifted its position in  Abbott Laboratories by 34.6% during the second quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker's stock worth $43,000 after purchasing an additional 81 shares during the period. 75.18% of the stock is currently owned by institutional investors. </p><h2>Wall Street Analyst Weigh In</h2><p>ABT has been the subject of several analyst reports. Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 16th. BTIG Research  reissued a &#34;buy&#34; rating and issued a $145.00 price objective on shares of Abbott Laboratories in a research note on Thursday, November 20th. Royal Bank Of Canada  restated an &#34;outperform&#34; rating and set a $147.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 16th. Benchmark initiated coverage on Abbott Laboratories in a report on Friday, October 10th. They issued a &#34;buy&#34; rating and a $145.00 target price on the stock. Finally, Wells Fargo &amp; Company boosted their price target on Abbott Laboratories from $142.00 to $146.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued  a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $147.00.</p><ul><li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li></ul><p><b>Get Our Latest Stock Report on ABT</b></p><h2>Abbott Laboratories Stock Down 0.4%</h2><p>Shares of NYSE:ABT opened at $125.30 on Thursday. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a market capitalization of $217.88 billion, a PE ratio of 15.70, a price-to-earnings-growth ratio of 2.29 and a beta of 0.72. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The company has a fifty day moving average of $126.06 and a 200-day moving average of $129.72. </p><ul><li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li></ul><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company had revenue of $11.37 billion for the quarter, compared to the consensus estimate of $11.40 billion. During the same quarter last year, the business posted $1.21 EPS. Abbott Laboratories's revenue for the quarter was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS.  On average, equities analysts predict that  Abbott Laboratories will post 5.14 EPS for the current fiscal year. </p><h2>Abbott Laboratories Increases Dividend</h2><p>The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a $0.63 dividend. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories's payout ratio is currently 29.57%. </p><h2>Abbott Laboratories Profile</h2> (Free Report)<p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.  </p><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Abbott Laboratories</li><li>The Best $1 You'll Spend This Holiday Season</li><li>Holiday surprise: $1 gets you everything</li><li>America’s “most deplorable” Christmas sale</li><li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li><li>Your family's wealth expires in 2026?</li></ul><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2><p>Before you consider Abbott Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Merit Financial Group LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 32.7% in Q3, acquiring an additional 20,035 shares, bringing its total to 81,264 shares valued at $10.88 million. Other institutional investors also raised their positions significantly. Analysts have a positive outlook on Abbott, with a consensus rating of "Moderate Buy" and an average price target of $147.00. Abbott's stock opened at $125.30, with a 52-week range of $110.86 to $141.23. The company reported Q3 earnings of $1.30 per share, meeting expectations, and has set FY 2025 guidance at 5.120-5.180 EPS.</p>

Merit Financial Group LLC Acquires 20,035 Shares of Abbott Laboratories $ABT